Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conventional antithrombotic approaches

J J Ferguson1

  • 1Cardiology Research Department, St. Luke's Episcopal Hospital, Houston, TX 77225, USA.

American Heart Journal
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Taylor's Power Law to Sample Statistics of Tylenchulus semipenetrans in Florida Citrus.

Journal of nematology·2009
Same author

Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.

Minerva cardioangiologica·2007
Same author

Optimal antithrombotic treatment for percutaneous coronary intervention.

Minerva cardioangiologica·2005
Same author

Noncompliance in antiplatelet trials: the AGATE trial perspective.

Stroke·2004
Same author

Symposium on 'influencing prescribing', Trinity College Dublin, Friday 20 June 1997.

Pharmacoepidemiology and drug safety·2004
Same author

Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin.

European journal of heart failure·2003
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Achieving adequate anticoagulation during percutaneous transluminal coronary angioplasty (PTCA) is crucial. Titrating heparin to specific activated clotting time (ACT) levels, like >275-300s (HemoTec) or >350-400s (Hemochron), can help prevent complications.

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Hematology

Background:

  • Thrombus formation during percutaneous transluminal coronary angioplasty (PTCA) increases risks of abrupt closure and procedural failure.
  • Ensuring adequate anticoagulation during PTCA is critical but subject to debate.
  • Low activated clotting time (ACT) has been linked to PTCA complications.

Purpose of the Study:

  • To evaluate the role of anticoagulation in preventing PTCA complications.
  • To provide recommendations for optimal anticoagulation strategies during PTCA.

Main Methods:

  • Review of existing studies on heparin anticoagulation and PTCA outcomes.
  • Analysis of the relationship between ACT levels and PTCA complication rates.
  • Evaluation of different ACT monitoring devices and target ranges.

Related Experiment Videos

Main Results:

  • No prospective studies definitively prove one ACT threshold superior to another.
  • Current data suggest targeting HemoTec ACT >275-300 seconds or Hemochron ACT >350-400 seconds.
  • Weight-based heparin dosing does not ensure predictable anticoagulation but may prevent overdose in lighter patients.

Conclusions:

  • Titrating anticoagulation to specific ACT levels is recommended for patients undergoing PTCA.
  • Monitoring ACT is essential for managing heparin therapy and minimizing procedural risks.
  • Further prospective studies are needed to establish definitive ACT thresholds.